Variables

HBP-Yes

HBP-No

OR^¶ [IC^‡_(95%)]

P-value

Duration of HIV infection

0.617

<5 years

45

(14.33%)

72

(22.93%)

1

[5 - 10[ years

37

(11.78%)

56

(17.84%)

1.05 [0.61 - 1.84]

10 - 15[ years

39

(12.42%)

43

(13.69%)

1.10 [0.80 - 2.57]

≥15 years

9

(2.87%)

13

(4.14%)

1.85 [0.43 - 2.80]

Duration of ARVs exposure

0.201

<5 years

42

(13.38%)

67

(21.34%)

1

[5 - 10[ years

38

(12.10%)

58

(18.47%)

1.04 [0.60 - 1.83]

10 - 15[ years

38

(12.10%)

45

(14.33%)

1.34 [0.75 - 2.40]

≥15 years

12

(3.82%)

14

(4.46%)

1.36 [0.58 - 3.24]

Virological failure status

0.463

No

112

(35.67%)

163

(51.91%)

1

Yes

18

(5.73%)

21

(6.69%)

1.37 [0.69 - 2.74]

Immunological failure status

0.982

No

114

(36.31%)

163

(51.91%)

1

Yes

16

(5.09%)

21

(6.69%)

1.07 [0.53 - 2.13]

Clinical failure status

0.723

No

126

(40.13%)

180

(57.33%)

1

Yes

4

(1.27%)

4

(1.27%)

1.41 [0.33 - 6.06]

Dyslipidemia

0.01

No

59

(18.79%)

117

(37.26%)

1

Yes

71

(22.61%)

67

(21.34%)

1.1 [0.76 - 1.48]

Total Hypercholesterolemia

<0.001*

No

65

(20.70%)

132

(42.04%)

1

Yes

65

(20.70%)

52

(16.56%)

2.54 [1.59 - 4.06]

LDL hypercholesterolemia

0.03*

No

109

(34.71%)

169

(53.82%)

1

Yes

21

(6.69%)

15

(4.78%)

1.4 [0.72 - 2.72]

HDL hypocholesterolemia

0.40

No

125

(39.81%)

173

(55.10%)

1

Yes

5

(1.59%)

11

(3.50%)

0.45 [0.15 - 1.30]

Hypertriglyceridemia

0.083

No

115

(36.62%)

173

(55.10%)

1

Yes

15

(4.78%)

11

(3.50%)

1.36 [0.62 - 2.97]